We are convinced that novel therapies will revolutionize obesity management.
As a result of comprehensive action on gut modulation, they will ensure safety, efficacy
and long-term results.
OBESITY & MICROBIOME
In a single decades, scientific research revealed the microbiome amazing abilities on health. Gut microbiota has emerged as a driving force in the development of obesity and its metabolic disorders.
While current strategies to prevent overweight and obesity have demonstrated their limitations, new therapies based on the microbiota now constitute the future for the fight against obesity.
go back to the site
On the strength of promising results obtained on Stablor,
LNC Therapeutics is heading a development projet called Temys project
WHAT TEMYS Project IS ABOUT ?
Through Temys Project, LNC Therapeutics is developing innovative gut microbiota directed drugs
INTESTINAL ECOSYSTEM MODULATION
Temys Project aims to restore intestinal ecosystem by microbiome modulation, inflammation decrease and gut permeability improvement (action on mucus, epithelium and tight junctions)
PATIENT PROFILE
- BMI > 25
-
Waist circumference
- > 94cm for men
- > 80cm for women
- 2 cardiometabolic risk factors
Discover Stablor, the first microbiome modulator against obesity
In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials
Discover our selection
Find out more